Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

Analysts at Zacks Research reduced their Q1 2025 earnings estimates for shares of RenaissanceRe in a research note issued to investors on Monday, February 10th. Zacks Research analyst K. Dey now ...

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Riot Platforms, Inc, an industry participant focused on vertically integrated Bitcoin mining, announced the appointment of ...

Carlyle is wrapping up a two-year fundraising campaign for its eighth secondaries flagship, CEO Harvey Schwartz said on the ...